What question did this study set out to answer?

January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-1167. Pharmacokinetics, Safety, and Tolerability of Funobactam in Combination with Imipenem/Cilastatin in Healthy Adult Elderly Male and Female Subjects

JLJianguo LiConcord Consortium QSQifeng ShiBD Biosciences (United States)JFJing FengBD Biosciences (United States)

Key Points

This research aimed to evaluate the pharmacokinetics, safety, and tolerability of funobactam in combination with imipenem.
Single intravenous administration of imipenem/cilastatin with funobactam in healthy elderly subjects.
Three cohorts: young females, elderly males, and elderly females.
Blood and urine samples were collected to assess drug concentrations using LC-MS/MS.
No significant age and gender effects on pharmacokinetics of funobactam were observed.
Mean Cmax for funobactam was highest in cohort 2 at 19.2 µg/mL.
Funobactam was found to be safe and well tolerated in all cohorts.

Abstract

Abstract Background Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent and selective direct activity against Ambler classes of A, C, D β–lactamases. Imipenem in combination with funobactam exhibits robust activity against carbapenem-resistant isolates of Enterobacterales, P. aeruginosa, and A. baumannii. This study evaluated pharmacokinetics (PK), safety, and tolerability of a single intravenous (IV) dose of imipenem 500 mg/ cilastatin 500 mg in combination with funobactam 250 mg in healthy adult elderly male and female subjects. Methods Eight subjects with 6 and 2 subjects randomized to active treatment or placebo, respectively, were enrolled into each of following 3 study cohorts: Cohort 1: Healthy young females≥ 18 to ≤ 45 years; Cohort 2: Healthy elderly males ≥ 65 years and Cohort 3: Healthy elderly females ≥ 65 years. Blood and urine samples were collected to determine funobactam, imipenem and cilastatin concentrations by LC-MS/MS method. The safety and tolerability were assessed by monitoring adverse events, ECGs, vital sign measurements, physical examinations, and clinical laboratory data. Results The mean (SD) of maximum concentration (Cmax), area under plasma concentration curve from zero to infinity (AUC0-∞,) plasma clearance (CL), volume of distribution at terminal phase (Vz), half-life (t1/2) and renal clearance (CLr) for funobactam are shown in the table below:PKParameter (units)Cohort 1 (N=6)Cohort 2 (N=6)Cohort 3 (N=6)Cmax (µg/mL)16.3 (2.6)19.2 (6.52)18.2 (5.03)AUC0-inf (µg*h/mL)45.0 (4.27)68.2 (26.6)63.0 (13.5)CL (L/h)5.59 (0.51)4.08 (1.35)4.11 (0.84)VZ (L)20.2 (1.35)21.3 (6.43)18.6 (4.83)t1/2 (h)2.51 (0.11)3.66 (0.39)3.10 (0.46)CLr4.54 (1.47)2.97 (0.63)3.42 (0.73) Conclusion Overall, there was no age and gender effect on the PK of funobactam after taking the difference in baseline creatinine into consideration. The single 60-minute IV administration of imipenem 500 mg/cilastatin500 mg in combination with funobactam 500 mg was safe and well tolerated in healthy adult elderly male and female subjects. Disclosures All Authors: No reported disclosures

问 AI

Bookmark

View Full Paper